Evidence map›Paper›PMID 41467200›Full record

ArticleAsian journal of urology2025

Targeting bladder cancer: Potent anti-cancer effects of cannabichromene and delta-9-tetrahydrocannabinol-rich

Omer Anis, Vered Bar, Adi Zundelevich, Seegehali M Anil, Yaron Shav-Tal, Amos Toren, Dan Dominissini, Gil Raviv, Menachem Laufer, Alon Lazarovich and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Omer AnisDepartment of Urology, Chaim Sheba Medical Center, Ramat-Gan, Israel.
Vered BarcResponce Company, Rehovot, Israel.
Adi ZundelevichcResponce Company, Rehovot, Israel.
Seegehali M AnilInstitute of Plant Science, Agricultural Research Organization, Volcani Center, Rehovot, Israel.
Yaron Shav-TalThe Mina & Everard Goodman Faculty of Life Sciences and Institute of Nanotechnology, Bar-Ilan University, Ramat-Gan, Israel.
Amos TorenCancer Research Center, Chaim Sheba Medical Center, Ramat-Gan, Israel.
Dan DominissiniCancer Research Center, Chaim Sheba Medical Center, Ramat-Gan, Israel.
Gil RavivDepartment of Urology, Chaim Sheba Medical Center, Ramat-Gan, Israel.
Menachem LauferDepartment of Urology, Chaim Sheba Medical Center, Ramat-Gan, Israel.
Alon LazarovichDepartment of Urology, Chaim Sheba Medical Center, Ramat-Gan, Israel.
Tomer DroriDepartment of Urology, Chaim Sheba Medical Center, Ramat-Gan, Israel.
Jacob RamonDepartment of Urology, Chaim Sheba Medical Center, Ramat-Gan, Israel.
Zohar DotanDepartment of Urology, Chaim Sheba Medical Center, Ramat-Gan, Israel.
Hinanit KoltaiInstitute of Plant Science, Agricultural Research Organization, Volcani Center, Rehovot, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study aimed to explore the anticancer potential of Methods: Results: Three commercial Conclusion: The findings suggest that

Indexed as

Bladder cancerCancerCannabinoidCannabisChemotherapyIntravesical instillationTissue cultureTransurethral resection of bladder tumorUrothelial carcinoma

Identifiers

PMID41467200
PMCPMC12744700

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.